Biopharmaceuticals, an Industrial Perspective
Editat de G. Walsh, B. Murphyen Limba Engleză Hardback – 30 sep 1999
The book is of particular relevance to scientists and allied professionals already employed in the biopharmaceutical industry, or to those seeking employment within this industry. Its scope also renders it an ideal reference source for students undertaking advanced undergraduate or postgraduate courses in biotechnology, pharmaceutical science, biochemistry or medicine.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1789.76 lei 43-57 zile | |
SPRINGER NETHERLANDS – 15 dec 2010 | 1789.76 lei 43-57 zile | |
Hardback (1) | 1795.93 lei 43-57 zile | |
SPRINGER NETHERLANDS – 30 sep 1999 | 1795.93 lei 43-57 zile |
Preț: 1795.93 lei
Preț vechi: 2190.15 lei
-18% Nou
Puncte Express: 2694
Preț estimativ în valută:
343.70€ • 357.02$ • 285.50£
343.70€ • 357.02$ • 285.50£
Carte tipărită la comandă
Livrare economică 03-17 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780792357469
ISBN-10: 0792357469
Pagini: 514
Ilustrații: X, 514 p.
Dimensiuni: 156 x 234 x 29 mm
Greutate: 0.92 kg
Ediția:1999
Editura: SPRINGER NETHERLANDS
Colecția Springer
Locul publicării:Dordrecht, Netherlands
ISBN-10: 0792357469
Pagini: 514
Ilustrații: X, 514 p.
Dimensiuni: 156 x 234 x 29 mm
Greutate: 0.92 kg
Ediția:1999
Editura: SPRINGER NETHERLANDS
Colecția Springer
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
Biopharmaceuticals, an overview.- Abciximab: The First Platelet Glycoprotein IIb/IIIa Receptor Antagonist.- Recombinant Coagulation Factor IX (BeneFix®).- Biopharmaceutical Drug Development: A Case History.- Follitropin beta (Puregon).- Insulin Lispro (Humalog).- Interferon beta-1b — the first long-term effective treatment of relapsing-remitting and secondary progressive multiple sclerosis (MS).- Reteplase, a recombinant plasminogen activator.- Stabilisation of biopharmaceutical products and finished product formulations.- Patent Law for Biopharmaceuticals.- The development of new medicines: an overview.- The EMEA and regulatory control of (bio)pharmaceuticals within the European Union.- Biopharmaceutical Validation: an overview.- Validation of Biopharmaceutical Chromatography Systems.- Validation of Water for Injections (WFI) for Biopharmaceutical Manufacture.- Information retrieval and the biopharmaceutical industry: an introductory overview.- Information technology and the internet as a resource of biopharmaceutical information.- Marketing Issues for the (Bio)pharmaceutical sector.- Viral mediated gene therapy.- Pharmaceutical gene medicines for non-viral gene therapy.